Core EM

OCTOBER 16, 2024

Author: Natalie Bertrand, MD Editor: Naillid Felipe, MD Background: Definition: adverse reaction to blood product administration Incidence: more common in children than adults, except for delayed hemolytic transfusion reactions Allergic (non-anaphylaxis) – Platelets 1-3%; RBCs 0.1-0.3%

Allergic Reaction 188

Allergic Reaction Plasma ED Epinephrine 188

REBEL EM

SEPTEMBER 13, 2023

Urticaria and pruritus = MAST CELL mediated, which is treated like a standard allergic reaction. Without the C1 inhibitor, the plasma-kallikrein-kinin system produces more bradykinin. Urticaria and pruritus = MAST CELL mediated, which is treated like a standard allergic reaction. N Engl J Med. 2015; 372(5):418-25.

Frozen Plasma 105

Frozen Plasma Allergic Reaction FFP Plasma 105

Core EM

OCTOBER 2, 2024

Author: Natalie Bertrand, MD Editor: Naillid Felipe, MD Background: Definition: adverse reaction to blood product administration Incidence: more common in children than adults, except for delayed hemolytic transfusion reactions Allergic (non-anaphylaxis) – Platelets 1-3%; RBCs 0.1-0.3%

Allergic Reaction 100

Allergic Reaction Plasma ED Epinephrine 100

EMDocs

AUGUST 31, 2023

Plasma half-life of the F(ab’) 2 antivenom is significantly longer at 5.5 F(ab) is smaller, consisting of a single antigen binding site, while F(ab’) 2 consists of two antigen-binding sites linked together by an antibody “hinge” region. This size difference may lead to differences in the pharmacokinetic profiles of the two antibodies.

Allergic Reaction 95

Allergic Reaction Plasma ALS EMS 95

ACEP Now

MAY 9, 2025

DDAVP causes release of endogenous coagulation factors such as factor VIII, von Willebrand factor (vWF), and tissue plasminogen activator (tPA) which increases plasma factor levels, enhances platelet adhesion, and reduces bleeding time. mcg/kg IV infused over 30 minutes Onset: within 30 minutes Peak effect: 1.5-2

Allergic Reaction 52

Allergic Reaction ALS Plasma Epinephrine 52